Suppr超能文献

口服普萘洛尔对增殖期婴幼儿血管瘤患儿尿碱性成纤维细胞生长因子、基质金属蛋白酶-2、基质金属蛋白酶-9表达的影响

[Effects of oral propranolol on urine bFGF, MMP-2, MMP-9 expression in children with proliferative infantile hemangioma].

作者信息

Yuan Wei-Li, Wang Xu-Kai

机构信息

Department of Stomatology, The Fourth Affiliated Hospital, China Medical University. Shenyang 110032, China. E-mail:

出版信息

Shanghai Kou Qiang Yi Xue. 2022 Aug;31(4):400-405.

Abstract

PURPOSE

To investigate the effect of propranolol on urine bFGF, MMP-2, MMP-9 expression of children with proliferative infantile hemangioma(IH), so as to clarify the mechanism of propranolol in treating IH.

METHODS

From June 2018 to June 2019, thirty-four children with proliferative IH were treated with oral propranolol. In addition, twenty-one normal children (age <12 months) were chosen as the control group. 10 mL of sterile morning urine were collected before and 2 months after oral administration of propranolol in infants with IH. All blood samples were placed in ordinary disinfection test tubes, centrifuged at 1 000 r/min for 10 min, the supernatant of urine was collected and stored separately. The urine samples of normal control group were processed in the same way. The expression levels of bFGF in the urine of children with proliferative IH before and 2 months after oral administration of propranolol and in the normal control group were detected by enzyme-linked immunosorbent assay (ELISA). The expression levels of MMP-2 and MMP-9 in the urine of children with proliferative IH before and 2 months after treatment and in the control group were detected by gelatin zymography. SPSS 22.0 software package was used to analyze the data.

RESULTS

Two months after oral propranolol treatment, the concentration of bFGF in urine was significantly lower than that before treatment (P<0.01), but still significantly higher than that in the control group (P<0.05). The expression levels of MMP-2 and MMP-9 were significantly lower than those before treatment(P<0.01), but still higher than those in the control group (P<0.05).

CONCLUSIONS

One of the mechanisms of propranolol in the treatment of children with proliferative IH may be through inhibiting the expression levels of bFGF, MMP-2 and MMP-9, and then inhibiting the proliferation and angiogenesis of vascular endothelial cells in IH, so as to achieve the effect of treating hemangioma. The detection of the expression levels of bFGF, MMP-2 and MMP-9 in urine can be used as the index for oral propranolol treatment of children with proliferative IH.

摘要

目的

探讨普萘洛尔对增殖期婴幼儿血管瘤(IH)患儿尿碱性成纤维细胞生长因子(bFGF)、基质金属蛋白酶-2(MMP-2)、基质金属蛋白酶-9(MMP-9)表达的影响,以阐明普萘洛尔治疗IH的机制。

方法

选取2018年6月至2019年6月期间34例增殖期IH患儿口服普萘洛尔进行治疗。另外,选取21例年龄<12个月的正常儿童作为对照组。收集IH患儿口服普萘洛尔前及服药2个月后的晨尿10 mL。所有血样均置于普通消毒试管中,以1 000 r/min离心10 min,分别收集尿液上清液并保存。正常对照组尿样按同样方法处理。采用酶联免疫吸附测定法(ELISA)检测增殖期IH患儿口服普萘洛尔前及服药2个月后以及正常对照组患儿尿液中bFGF的表达水平。采用明胶酶谱法检测增殖期IH患儿治疗前及治疗2个月后以及对照组患儿尿液中MMP-2和MMP-9的表达水平。采用SPSS 22.0软件包进行数据分析。

结果

口服普萘洛尔治疗2个月后,患儿尿中bFGF浓度显著低于治疗前(P<0.01),但仍显著高于对照组(P<0.05)。MMP-2和MMP-9的表达水平显著低于治疗前(P<0.01),但仍高于对照组(P<0.05)。

结论

普萘洛尔治疗增殖期IH患儿的机制之一可能是通过抑制bFGF、MMP-2和MMP-9的表达水平,进而抑制IH血管内皮细胞的增殖和血管生成,从而达到治疗血管瘤的效果。检测尿液中bFGF、MMP-2和MMP-9的表达水平可作为口服普萘洛尔治疗增殖期IH患儿的指标。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验